PharmaCyte Biotech (PMCB) stock: insider trades, news & valuation
Net buyingShare price and insider trades
PharmaCyte Biotech insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $128K and 0 sold $0 of PMCB stock on the open market.
Get emailed when insiders cluster-buy stocks like PMCB
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
PMCB insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $128K | 6 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 PharmaCyte Biotech, Inc. insiders reported open-market purchases totaling $128K, while 0 insiders reported sales totaling $0. Among insiders with enough purchase history to measure, Jonathan Schechter (Director) has the highest Insider Score at 8.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jan 7SEC | Joshua SilvermanCEO, President | Buy | 40,000416,250 held (+11%) | $0.83 | $33K | -51.3% | — |
| Jan 7SEC | Joshua SilvermanCEO, President | Buy | 30,000376,250 held (+9%) | $0.79 | $24K | -48.8% | — |
| Jan 7SEC | Joshua SilvermanCEO, President | Buy | 30,000346,250 held (+9%) | $0.78 | $23K | -48.2% | — |
| Jan 7SEC | Jonathan SchechterDirector | Buy | 20,000192,500 held (+12%) | $0.84 | $17K | -51.9% | 8 |
| Jan 7SEC | Jonathan SchechterDirector | Buy | 20,000172,500 held (+13%) | $0.79 | $16K | -48.8% | 8 |
| Jan 7SEC | Jonathan SchechterDirector | Buy | 20,000152,500 held (+15%) | $0.78 | $16K | -48.2% | 8 |
Insiders at PharmaCyte Biotech, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Joshua SilvermanCEO, President | $80K | — | Jan 7, 2026 | — |
| Jonathan SchechterDirector | $48K | — | Jan 7, 2026 | 8 |
PMCB stock: common questions
Are PharmaCyte Biotech, Inc. insiders buying PMCB stock?
In the past 12 months, 2 insiders reported open-market purchases of PMCB worth $128K. The latest was CEO, President Joshua Silverman bought $33K of PMCB at $0.83 — largest purchase by this insider in our records.
Are PharmaCyte Biotech, Inc. insiders selling PMCB stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is PMCB's 52-week range?
Over the past year PMCB has traded between $0.38 and $1.22. It last closed at $0.40 on Oct 9, 2026.